Tongxinluo capsule as supplementation and cardiovascular endpoint events in patients with coronary heart disease: A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials.

Author: CuiXiangning, GaoJialiang, GuoShasha, LiuShixu, LvJiayu, SongQingqiao

Paper Details 
Original Abstract of the Article :
ETHNOPHARMACOLOGICAL RELEVANCE: Tongxinluo Capsule(TXLC) is a well-known traditional Chinese medicine prescription with effects of tonifying Qi and activating blood based on the Chinese herbal medicine theory that has been recommended as routine adjuvant treatment in patients with coronary heart dis...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://doi.org/10.1016/j.jep.2022.115033

データ提供:米国国立医学図書館(NLM)

Tongxinluo Capsule as Supplementation for Cardiovascular Health

This comprehensive meta-analysis sheds light on the efficacy and safety of Tongxinluo Capsule (TXLC), a traditional Chinese medicine prescription, in preventing adverse cardiovascular events in patients with coronary heart disease (CHD). The researchers meticulously analyzed data from 11 randomized controlled trials (RCTs) involving 1505 patients, comparing the effects of TXLC supplementation to placebo. Their findings indicated that TXLC supplementation significantly reduced the risk of myocardial infarction (MI), target vessel revascularization (TVR) or in-stent restenosis (ISR), cerebrovascular accidents, heart failure (HF), and unscheduled readmission for cardiovascular diseases (CVDs).

TXLC Shows Promise in Cardiovascular Care

This meta-analysis paints a promising picture for TXLC as a potential adjunctive therapy for CHD patients. The observed reduction in cardiovascular events suggests that TXLC may play a role in improving overall cardiovascular health. However, the study also highlighted the need for further research with larger sample sizes and extended follow-up periods to solidify these findings and explore its effects on cardiovascular mortality.

Heart Health in the Desert of Time

Imagine a caravan traversing a vast desert, each traveler representing a CHD patient. TXLC acts like a reliable camel, providing support and reducing the risk of encountering treacherous cardiovascular events. While this meta-analysis suggests a potential benefit, we need to further investigate the long-term effects of this ancient remedy to ensure its safety and effectiveness in managing the demanding journey of cardiovascular health.

Dr. Camel's Conclusion

This meta-analysis suggests that TXLC supplementation may hold promise for preventing cardiovascular events in patients with CHD. However, larger-scale studies with longer follow-up periods are needed to confirm these findings and further explore the role of TXLC in improving cardiovascular health.
Date :
  1. Date Completed 2022-03-14
  2. Date Revised 2022-03-14
Further Info :

Pubmed ID

35091010

DOI: Digital Object Identifier

10.1016/j.jep.2022.115033

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.